Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Want to see HK:2315 full AI Analyst Report?
2315 Stock Chart & Stats
HK$28.70
-HK$0.07(-0.93%)
At close: 4:00 PM EST
HK$28.70
-HK$0.07(-0.93%)
Day’s Range― - ―
52-Week RangeHK$11.58 - HK$70.15
Previous CloseN/A
Volume49.50K
Average Volume (3M)488.12K
Market Cap
HK$24.51B
Enterprise ValueHK$17.18B
Total Cash (Recent Filing)HK$1.56B
Total Debt (Recent Filing)HK$584.09M
Price to Earnings (P/E)73.2
Beta1.12
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$57.72Price Target Upside101.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.74
Revenue Forecast (FY)HK$1.86B
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & High Gross MarginsSustained multi-year revenue growth combined with very high gross margins indicates strong product/service economics and expanding market adoption. Durable unit economics support reinvestment in R&D and partnerships, enabling scalable margin-accretive growth over multiple years.
Profitability Inflection And Improved MarginsA clear shift from multi-year losses to positive net and EBIT margins shows operational leverage and better cost control. Durable profitability reduces reliance on external capital, improves strategic optionality, and signals management can convert growth into sustainable earnings.
Proprietary Discovery Platforms & Partner ModelOwning gene-edited platforms and offering discovery/preclinical services creates a technical moat and recurring, contractable revenue streams. Strategic partnerships diversify development risk and provide long-term collaboration income beyond internal pipeline milestones.
Bears Say
Durability Risk From Recent Losses And FCF DipAlthough profitability has emerged, the company was loss-making through 2023 and saw free cash flow decline in 2025, highlighting sensitivity to execution. In biotech, swings in program timing or partner activity can quickly reverse margins and cash, testing durability.
Volatile Capital StructureSignificant year-to-year shifts in leverage and equity levels signal past financing variability. Such volatility can reflect dilution or refinancing events that reduce financial flexibility, which is a structural risk if revenue or cash generation weakens.
History Of Multi-year Cash OutflowsPrior multi-year operating and free cash outflows show the business previously required external funding to operate. A recent FCF decline despite profitability suggests cash generation remains sensitive and may not yet be reliably cyclical, raising funding risk in downturns.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News
2315 FAQ
What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$11.58 and its highest was HK$70.15 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$24.51B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 126 days.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$0.264 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.264.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
According to Wall Street analysts Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price is currently Undervalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of HK$0.264 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.917%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
476.71%
12-Months-Change
Fundamentals
Return on Equity
8.62%
Trailing 12-Months
Asset Growth
61.38%
Trailing 12-Months
Company Description
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Earnings & Revenues
2315 Stock 12 Month Forecast
Average Price Target
HK$57.72
▲(101.11% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---